Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410845 | 1.00 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CBMTOROPRK1 | |
| SCHEMBL20766476 | 0.85 | PTGS2 (0.42) | OPRK1PTGS2 | |
| SCHEMBL30410749 | 0.85 | PTGS2 (0.42) | OPRK1PTGS2 | |
| SCHEMBL20766736 | 0.82 | PTGS2 (0.43) | PIK3CGPTGS2 | |
| SCHEMBL20779695 | 0.79 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL22646179 | 0.77 | TNNI3K (0.43) | PIK3CDPIK3CGPIK3CBMTOR | |
| SCHEMBL20767455 | 0.77 | BRD4 (0.41) | PTGS2 | |
| SCHEMBL20766828 | 0.77 | ALOX15 (0.44) | PTGS2 | |
| SCHEMBL20766392 | 0.77 | PTGS1 (0.44) | PTGS2 | |
| SCHEMBL30410106 | 0.76 | BRD4 (0.43) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | PIK3CD 2083/4885PIK3CG 2605/4885PIK3CB 1634/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | PIK3CD 3347/4885PIK3CG 4530/4885PIK3CB 4338/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | PIK3CD 2083/4885PIK3CG 2605/4885PIK3CB 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.